{"protocolSection": {"identificationModule": {"nctId": "NCT01479595", "orgStudyIdInfo": {"id": "CQBX258X2201"}, "secondaryIdInfos": [{"id": "2011-003066-32", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "A Study to Establish the Efficacy of QBX258 in Patients With Moderate to Severe Asthma", "officialTitle": "A Randomized Double-blind Multiple-dose Placebo-controlled Trial to Establish the Efficacy of QBX258 (Combination of VAK694 and QAX576) in Asthma That is Inadequately Controlled With Inhaled Corticosteroids and Long Acting Beta Agonists"}, "statusModule": {"statusVerifiedDate": "2016-06", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2012-02"}, "primaryCompletionDateStruct": {"date": "2015-02", "type": "ACTUAL"}, "completionDateStruct": {"date": "2015-02", "type": "ACTUAL"}, "studyFirstSubmitDate": "2011-11-22", "studyFirstSubmitQcDate": "2011-11-23", "studyFirstPostDateStruct": {"date": "2011-11-24", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2016-02-23", "resultsFirstSubmitQcDate": "2016-06-20", "resultsFirstPostDateStruct": {"date": "2016-08-01", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-06-20", "lastUpdatePostDateStruct": {"date": "2016-08-01", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novartis Pharmaceuticals", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This study is designed to investigate the efficacy and safety of QBX258 in subjects with moderate to severe asthma."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Asthma", "Interleukin", "QBX258", "QAX576", "VAK694"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 65, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "QBX258", "type": "EXPERIMENTAL", "description": "Participants received QBX258 intravenous (iv) infusion every 4 weeks for up to 4 doses total.", "interventionNames": ["Drug: QBX258"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Participants received placebo to QBX258 iv infusion every 4 weeks for up to 4 doses total.", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "QBX258", "description": "QBX258 infusion, a combination of VAK694 and QAX576, was supplied to the Investigator as open label bulk medication. The planned dose of VAK694 (lyophilisate in vial, 150 mg/vial), was 3 mg/kg. The planned dose of QAX576 (lyophilisate in vial, 150 mg/vial), was 6 mg/kg.", "armGroupLabels": ["QBX258"]}, {"type": "DRUG", "name": "Placebo", "description": "The placebo infusion was an equal volume of 5% dextrose for infusion and was provided by the clinical site.", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Asthma Control Questionnaire (ACQ) Score", "description": "The ACQ consists of 7 questions assessing symptoms, rescue medication use and lung function. Except for lung function (FEV1), each question was scored on a 7-point scale where 0 = no impairment and 6 = maximum impairment. Scores ranged between 0 totally controlled to 6 (severely uncontrolled). Participants with a score below 1.0 are considered to have adequately controlled asthma. Participants with a score above 1.0 were considered not to be well controlled. A negative change from baseline indicates improvement.", "timeFrame": "Baseline and 12 weeks"}], "secondaryOutcomes": [{"measure": "Change in Forced Expiratory Volume in One Second (FEV1)", "description": "FEV1 was assessed using central spirometry according to the American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines.", "timeFrame": "Baseline and 12 weeks"}, {"measure": "Change in Asthma Quality of Life Questionnaire (AQLQ) Score", "description": "The AQLQ is a 32-item disease specific questionnaire designed to measure functional impairments that are most important to patients with asthma. It consists of 4 domains: symptoms, emotions., exposure to environmental stimuli and activity limitation.\n\nPatients were asked to recall their experiences during the previous 2 weeks and to score each item on a 7-point scale. The scale ranges from 1 to 7. The overall AQLQ score was the mean response to all 32 questions. Higher scores represent better outcomes.", "timeFrame": "Baseline and 12 weeks"}, {"measure": "Morning and Evening Peak Expiratory Flow (PEF) Rate", "description": "Morning and evening PEFs were recorded on an electronic diary (e-diary). PEF was assessed twice daily approximately 12 hours apart and the measurements were recorded in the e-diary.", "timeFrame": "Baseline and 12 weeks"}, {"measure": "Change From Baseline in Maximum Expiratory Flow", "description": "Maximum expiratory flow was assessed using central spirometry according to the American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines.", "timeFrame": "Baseline and 12 weeks"}, {"measure": "Number of Participants With Anti-QAX576 Antibodies or Anti-VAK694 Antibodies", "description": "Anti-QAX576 and anti-VAK694 antibodies in serum were analyzed.", "timeFrame": "12 weeks"}, {"measure": "Observed Maximum Plasma Concentration Following Drug Administration at Steady State (Cmax,ss) of the QAX576 Analyte", "description": "Blood samples were obtained to measure Cmax,ss.", "timeFrame": "days 1 (pre-dose and 2 hours post-dose), 15, 29 (pre-dose and 2 hours post-dose), 43, 57 (pre-dose and 2 hours post-dose), 71, 85 (pre-dose and 2 hours post-dose), 99, 113, 141, 183"}, {"measure": "Observed Maximum Plasma Concentration Following Drug Administration at Steady State (Cmax,ss) of the VAK694 Analyte", "description": "Blood samples were obtained to measure Cmax,ss.", "timeFrame": "days 1 (pre-dose and 2 hours post-dose), 15, 29 (pre-dose and 2 hours post-dose), 43, 57 (pre-dose and 2 hours post-dose), 71, 85 (pre-dose and 2 hours post-dose), 99, 113, 141, 183"}, {"measure": "Lowest Plasma Concentration Observed During a Dosing Interval at Steady State (Cmin,ss) of the QAX576 Analyte", "description": "Blood samples were obtained to measure Cmin,ss.", "timeFrame": "days 1 (pre-dose and 2 hours post-dose), 15, 29 (pre-dose and 2 hours post-dose), 43, 57 (pre-dose and 2 hours post-dose), 71, 85 (pre-dose and 2 hours post-dose), 99, 113, 141, 183"}, {"measure": "Lowest Plasma Concentration Observed During a Dosing Interval at Steady State (Cmin,ss) of the VAK694 Analyte", "description": "Blood samples were obtained to measure Cmin,ss.", "timeFrame": "days 1 (pre-dose and 2 hours post-dose), 15, 29 (pre-dose and 2 hours post-dose), 43, 57 (pre-dose and 2 hours post-dose), 71, 85 (pre-dose and 2 hours post-dose), 99, 113, 141, 183"}, {"measure": "Change From Baseline in Fractional Exhaled Nitric Oxide (FeNO)", "description": "FeNO was assessed as a measure of airway inflammation. An FeNO machine was used to obtain the FeNO measurements. FeNO measurements were obtained prior to the spirometry assessments.", "timeFrame": "baseline, 12 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with atopic asthma \\>1 year duration diagnosed according to the GINA guidelines.\n* Subjects must weigh at least 50 kg to participate in the study, and must have a body mass index (BMI) within the range of 18 - 39 kg/m2.\n* Asthma which is not adequately controlled on current treatment, as demonstrated by an Asthma Control Questionnaire (ACQ) score of \\> 1.5.\n* FEV1 40 to 90% of predicted.\n\nExclusion Criteria:\n\n* Diagnosed with COPD as defined by the GOLD guidelines\n* Subjects who have had a respiratory tract infection within 4 weeks prior to screening.\n* Women of child-bearing potential must use highly effective methods of contraception during dosing and for at least 18 weeks after last study drug administration", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "65 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis Pharmaceuticals", "affiliation": "Novartis Pharmaceuticals", "role": "STUDY_DIRECTOR"}, {"name": "Novartis Pharmaceuticals", "affiliation": "Novartis", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Novartis Investigative Site", "city": "Anaheim", "state": "California", "zip": "92801", "country": "United States", "geoPoint": {"lat": 33.83529, "lon": -117.9145}}, {"facility": "Novartis Investigative Site", "city": "Riverside", "state": "California", "zip": "92506", "country": "United States", "geoPoint": {"lat": 33.95335, "lon": -117.39616}}, {"facility": "Novartis Investigative Site", "city": "Rolling Hills Estates", "state": "California", "zip": "90274", "country": "United States", "geoPoint": {"lat": 33.78779, "lon": -118.35813}}, {"facility": "Novartis Investigative Site", "city": "San Marino", "state": "California", "zip": "91108", "country": "United States", "geoPoint": {"lat": 34.1214, "lon": -118.10646}}, {"facility": "Novartis Investigative Site", "city": "Denver", "state": "Colorado", "zip": "80206", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "Novartis Investigative Site", "city": "Denver", "state": "Colorado", "zip": "80230", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "Novartis Investigative Site", "city": "Aventura", "state": "Florida", "zip": "33180", "country": "United States", "geoPoint": {"lat": 25.95648, "lon": -80.13921}}, {"facility": "Novartis Investigative Site", "city": "Boston", "state": "Massachusetts", "zip": "02115", "country": "United States", "geoPoint": {"lat": 42.35843, "lon": -71.05977}}, {"facility": "Novartis Investigative Site", "city": "Minneapolis", "state": "Minnesota", "zip": "55402", "country": "United States", "geoPoint": {"lat": 44.97997, "lon": -93.26384}}, {"facility": "Novartis Investigative Site", "city": "St. Louis", "state": "Missouri", "zip": "63110", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Novartis Investigative Site", "city": "Raleigh", "state": "North Carolina", "zip": "27607", "country": "United States", "geoPoint": {"lat": 35.7721, "lon": -78.63861}}, {"facility": "Novartis Investigative Site", "city": "Winston-Salem", "state": "North Carolina", "zip": "27157", "country": "United States", "geoPoint": {"lat": 36.09986, "lon": -80.24422}}, {"facility": "Novartis Investigative Site", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73120", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Novartis Investigative Site", "city": "Medford", "state": "Oregon", "zip": "97504-8741", "country": "United States", "geoPoint": {"lat": 42.32652, "lon": -122.87559}}, {"facility": "Novartis Investigative Site", "city": "Spartanburg", "state": "South Carolina", "zip": "29303", "country": "United States", "geoPoint": {"lat": 34.94957, "lon": -81.93205}}, {"facility": "Novartis Investigative Site", "city": "Berlin", "zip": "10117", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Novartis Investigative Site", "city": "Frankfurt", "zip": "60596", "country": "Germany", "geoPoint": {"lat": 50.11552, "lon": 8.68417}}, {"facility": "Novartis Investigative Site", "city": "Wiesbaden", "zip": "65187", "country": "Germany", "geoPoint": {"lat": 50.08258, "lon": 8.24932}}, {"facility": "Novartis Investigative Site", "city": "London", "zip": "SE11YR", "country": "United Kingdom", "geoPoint": {"lat": 51.50853, "lon": -0.12574}}, {"facility": "Novartis Investigative Site", "city": "Manchester", "zip": "M23 9QZ", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}]}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "Participants were assigned to either QBX258 or placebo in a 2:1 ratio. Randomization was done by stratification of Q576R.", "groups": [{"id": "FG000", "title": "QBX258", "description": "Participants received QBX258 intravenous (iv) infusion every 4 weeks for up to 4 doses total."}, {"id": "FG001", "title": "Placebo", "description": "Participants received placebo to QBX258 iv infusion every 4 weeks for up to 4 doses total."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "44"}, {"groupId": "FG001", "numSubjects": "21"}]}, {"type": "PK Analysis Set", "achievements": [{"groupId": "FG000", "numSubjects": "42"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Per Protocol Analysis Set", "achievements": [{"groupId": "FG000", "numSubjects": "41"}, {"groupId": "FG001", "numSubjects": "20"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "42"}, {"groupId": "FG001", "numSubjects": "19"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}]}], "dropWithdraws": [{"type": "Protocol deviation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "QBX258", "description": "Participants received QBX258 intravenous (iv) infusion every 4 weeks for up to 4 doses total."}, {"id": "BG001", "title": "Placebo", "description": "Participants received placebo to QBX258 iv infusion every 4 weeks for up to 4 doses total."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "44"}, {"groupId": "BG001", "value": "21"}, {"groupId": "BG002", "value": "65"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "42.5", "spread": "11.71"}, {"groupId": "BG001", "value": "42.8", "spread": "13.54"}, {"groupId": "BG002", "value": "42.6", "spread": "12.22"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "23"}, {"groupId": "BG001", "value": "11"}, {"groupId": "BG002", "value": "34"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "21"}, {"groupId": "BG001", "value": "10"}, {"groupId": "BG002", "value": "31"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Asthma Control Questionnaire (ACQ) Score", "description": "The ACQ consists of 7 questions assessing symptoms, rescue medication use and lung function. Except for lung function (FEV1), each question was scored on a 7-point scale where 0 = no impairment and 6 = maximum impairment. Scores ranged between 0 totally controlled to 6 (severely uncontrolled). Participants with a score below 1.0 are considered to have adequately controlled asthma. Participants with a score above 1.0 were considered not to be well controlled. A negative change from baseline indicates improvement.", "populationDescription": "Participants from the per-protocol analysis set were considered for the analysis. Only participants who had both baseline and week 12 values were included in the analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "score on a scale", "timeFrame": "Baseline and 12 weeks", "groups": [{"id": "OG000", "title": "QBX258", "description": "Participants received QBX258 intravenous (iv) infusion every 4 weeks for up to 4 doses total."}, {"id": "OG001", "title": "Placebo", "description": "Participants received placebo to QBX258 iv infusion every 4 weeks for up to 4 doses total."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "41"}, {"groupId": "OG001", "value": "19"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.513", "spread": "0.0970"}, {"groupId": "OG001", "value": "0.001", "spread": "0.1487"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.005", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Net)", "paramValue": "-0.514", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.811", "ciUpperLimit": "-0.217"}]}, {"type": "SECONDARY", "title": "Change in Forced Expiratory Volume in One Second (FEV1)", "description": "FEV1 was assessed using central spirometry according to the American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines.", "populationDescription": "Participants from the per-protocol analysis set were considered for the analysis. Only participants who had both baseline and week 12 values were included in the analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liters", "timeFrame": "Baseline and 12 weeks", "groups": [{"id": "OG000", "title": "QBX258", "description": "Participants received QBX258 intravenous (iv) infusion every 4 weeks for up to 4 doses total."}, {"id": "OG001", "title": "Placebo", "description": "Participants received placebo to QBX258 iv infusion every 4 weeks for up to 4 doses total."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "41"}, {"groupId": "OG001", "value": "19"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.076", "spread": "0.0528"}, {"groupId": "OG001", "value": "0.050", "spread": "0.0770"}]}]}]}, {"type": "SECONDARY", "title": "Change in Asthma Quality of Life Questionnaire (AQLQ) Score", "description": "The AQLQ is a 32-item disease specific questionnaire designed to measure functional impairments that are most important to patients with asthma. It consists of 4 domains: symptoms, emotions., exposure to environmental stimuli and activity limitation.\n\nPatients were asked to recall their experiences during the previous 2 weeks and to score each item on a 7-point scale. The scale ranges from 1 to 7. The overall AQLQ score was the mean response to all 32 questions. Higher scores represent better outcomes.", "populationDescription": "Participants from the per-protocol analysis set were considered for the analysis. Only participants who had both baseline and week 12 values were included in the analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "score on a scale", "timeFrame": "Baseline and 12 weeks", "groups": [{"id": "OG000", "title": "QBX258", "description": "Participants received QBX258 intravenous (iv) infusion every 4 weeks for up to 4 doses total."}, {"id": "OG001", "title": "Placebo", "description": "Participants received placebo to QBX258 iv infusion every 4 weeks for up to 4 doses total."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "40"}, {"groupId": "OG001", "value": "19"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.580", "spread": "0.1294"}, {"groupId": "OG001", "value": "0.468", "spread": "0.1878"}]}]}]}, {"type": "SECONDARY", "title": "Morning and Evening Peak Expiratory Flow (PEF) Rate", "description": "Morning and evening PEFs were recorded on an electronic diary (e-diary). PEF was assessed twice daily approximately 12 hours apart and the measurements were recorded in the e-diary.", "populationDescription": "No analysis was performed on the collected data with the eDiary device due to overall poor data quality (values were obtained that were not physiologically possible) and high variability. Therefore, there is no data to present for this outcome measure.", "reportingStatus": "POSTED", "timeFrame": "Baseline and 12 weeks", "groups": [{"id": "OG000", "title": "QBX258", "description": "Participants received QBX258 intravenous (iv) infusion every 4 weeks for up to 4 doses total."}, {"id": "OG001", "title": "Placebo", "description": "Participants received placebo to QBX258 iv infusion every 4 weeks for up to 4 doses total."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Maximum Expiratory Flow", "description": "Maximum expiratory flow was assessed using central spirometry according to the American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines.", "populationDescription": "Participants from the per-protocol analysis set were considered for the analysis. Only participants who had both baseline and week 12 values were included in the analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "L/sec", "timeFrame": "Baseline and 12 weeks", "groups": [{"id": "OG000", "title": "QBX258", "description": "Participants received QBX258 intravenous (iv) infusion every 4 weeks for up to 4 doses total."}, {"id": "OG001", "title": "Placebo", "description": "Participants received placebo to QBX258 iv infusion every 4 weeks for up to 4 doses total."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "41"}, {"groupId": "OG001", "value": "19"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.099", "spread": "0.4270"}, {"groupId": "OG001", "value": "0.025", "spread": "0.3000"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Anti-QAX576 Antibodies or Anti-VAK694 Antibodies", "description": "Anti-QAX576 and anti-VAK694 antibodies in serum were analyzed.", "populationDescription": "All randomized participants", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "12 weeks", "groups": [{"id": "OG000", "title": "QBX258", "description": "Participants received QBX258 intravenous (iv) infusion every 4 weeks for up to 4 doses total."}, {"id": "OG001", "title": "Placebo", "description": "Participants received placebo to QBX258 iv infusion every 4 weeks for up to 4 doses total."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "44"}, {"groupId": "OG001", "value": "21"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "2"}]}]}]}, {"type": "SECONDARY", "title": "Observed Maximum Plasma Concentration Following Drug Administration at Steady State (Cmax,ss) of the QAX576 Analyte", "description": "Blood samples were obtained to measure Cmax,ss.", "populationDescription": "Participants from the per-protocol analysis set were considered for the analysis. Only participants who had week 12 values were included in the analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/mL", "timeFrame": "days 1 (pre-dose and 2 hours post-dose), 15, 29 (pre-dose and 2 hours post-dose), 43, 57 (pre-dose and 2 hours post-dose), 71, 85 (pre-dose and 2 hours post-dose), 99, 113, 141, 183", "groups": [{"id": "OG000", "title": "QBX258", "description": "Participants received QBX258 intravenous (iv) infusion every 4 weeks for up to 4 doses total."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "40"}]}], "classes": [{"title": "Q576R SNP stratum: QQ (n=21)", "categories": [{"measurements": [{"groupId": "OG000", "value": "169000", "spread": "47000"}]}]}, {"title": "Q576R SNP stratum: RR/QR (n=19)", "categories": [{"measurements": [{"groupId": "OG000", "value": "184000", "spread": "85000"}]}]}, {"title": "QBX258 (n=40)", "categories": [{"measurements": [{"groupId": "OG000", "value": "176000", "spread": "67300"}]}]}]}, {"type": "SECONDARY", "title": "Observed Maximum Plasma Concentration Following Drug Administration at Steady State (Cmax,ss) of the VAK694 Analyte", "description": "Blood samples were obtained to measure Cmax,ss.", "populationDescription": "Participants from the per-protocol analysis set were considered for the analysis. Only participants who had week 12 values were included in the analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ug/mL", "timeFrame": "days 1 (pre-dose and 2 hours post-dose), 15, 29 (pre-dose and 2 hours post-dose), 43, 57 (pre-dose and 2 hours post-dose), 71, 85 (pre-dose and 2 hours post-dose), 99, 113, 141, 183", "groups": [{"id": "OG000", "title": "QBX258", "description": "Participants received QBX258 intravenous (iv) infusion every 4 weeks for up to 4 doses total."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "40"}]}], "classes": [{"title": "Q576R SNP stratum: QQ (n=21)", "categories": [{"measurements": [{"groupId": "OG000", "value": "56.7", "spread": "8.90"}]}]}, {"title": "Q576R SNP stratum: RR/QR (n=19)", "categories": [{"measurements": [{"groupId": "OG000", "value": "58.6", "spread": "14.9"}]}]}, {"title": "QBX258 (n=40)", "categories": [{"measurements": [{"groupId": "OG000", "value": "57.6", "spread": "12.0"}]}]}]}, {"type": "SECONDARY", "title": "Lowest Plasma Concentration Observed During a Dosing Interval at Steady State (Cmin,ss) of the QAX576 Analyte", "description": "Blood samples were obtained to measure Cmin,ss.", "populationDescription": "Participants from the per-protocol analysis set were considered for the analysis. Only participants who had week 12 values were included in the analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/mL", "timeFrame": "days 1 (pre-dose and 2 hours post-dose), 15, 29 (pre-dose and 2 hours post-dose), 43, 57 (pre-dose and 2 hours post-dose), 71, 85 (pre-dose and 2 hours post-dose), 99, 113, 141, 183", "groups": [{"id": "OG000", "title": "QBX258", "description": "Participants received QBX258 intravenous (iv) infusion every 4 weeks for up to 4 doses total."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "40"}]}], "classes": [{"title": "Q576R SNP stratum: QQ (n=21)", "categories": [{"measurements": [{"groupId": "OG000", "value": "37500", "spread": "11900"}]}]}, {"title": "Q576R SNP stratum: RR/QR (n=19)", "categories": [{"measurements": [{"groupId": "OG000", "value": "32200", "spread": "9930"}]}]}, {"title": "QBX258 (n=40)", "categories": [{"measurements": [{"groupId": "OG000", "value": "35000", "spread": "11200"}]}]}]}, {"type": "SECONDARY", "title": "Lowest Plasma Concentration Observed During a Dosing Interval at Steady State (Cmin,ss) of the VAK694 Analyte", "description": "Blood samples were obtained to measure Cmin,ss.", "populationDescription": "Participants from the per-protocol analysis set were considered for the analysis. Only participants who had week 12 values were included in the analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ug/mL", "timeFrame": "days 1 (pre-dose and 2 hours post-dose), 15, 29 (pre-dose and 2 hours post-dose), 43, 57 (pre-dose and 2 hours post-dose), 71, 85 (pre-dose and 2 hours post-dose), 99, 113, 141, 183", "groups": [{"id": "OG000", "title": "QBX258", "description": "Participants received QBX258 intravenous (iv) infusion every 4 weeks for up to 4 doses total."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "40"}]}], "classes": [{"title": "Q576R SNP stratum: QQ (n=21)", "categories": [{"measurements": [{"groupId": "OG000", "value": "10.7", "spread": "2.69"}]}]}, {"title": "Q576R SNP stratum: RR/QR (n=19)", "categories": [{"measurements": [{"groupId": "OG000", "value": "9.83", "spread": "2.94"}]}]}, {"title": "QBX258 (n=40)", "categories": [{"measurements": [{"groupId": "OG000", "value": "10.3", "spread": "2.81"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fractional Exhaled Nitric Oxide (FeNO)", "description": "FeNO was assessed as a measure of airway inflammation. An FeNO machine was used to obtain the FeNO measurements. FeNO measurements were obtained prior to the spirometry assessments.", "populationDescription": "Participants from the per-protocol analysis set were considered for the analysis. Only participants who had both baseline and week 12 values were included in the analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "parts per billion (ppb)", "timeFrame": "baseline, 12 weeks", "groups": [{"id": "OG000", "title": "QBX258", "description": "Participants received QBX258 intravenous (iv) infusion every 4 weeks for up to 4 doses total."}, {"id": "OG001", "title": "Placebo", "description": "Participants received placebo to QBX258 iv infusion every 4 weeks for up to 4 doses total."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "36"}, {"groupId": "OG001", "value": "15"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-3.67", "spread": "3.580"}, {"groupId": "OG001", "value": "2.21", "spread": "5.393"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "QBX258", "description": "Participants received QBX258 intravenous (iv) infusion every 4 weeks for up to 4 doses total.", "seriousNumAffected": 1, "seriousNumAtRisk": 44, "otherNumAffected": 13, "otherNumAtRisk": 44}, {"id": "EG001", "title": "Placebo", "description": "Participants received placebo to QBX258 iv infusion every 4 weeks for up to 4 doses total.", "seriousNumAffected": 1, "seriousNumAtRisk": 21, "otherNumAffected": 7, "otherNumAtRisk": 21}], "seriousEvents": [{"term": "ABORTION", "organSystem": "Pregnancy, puerperium and perinatal conditions", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 44}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 21}]}, {"term": "LARYNGEAL OEDEMA", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 44}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 21}]}], "otherEvents": [{"term": "NAUSEA", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 44}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 21}]}, {"term": "VOMITING", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 44}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 21}]}, {"term": "NASOPHARYNGITIS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 44}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 21}]}, {"term": "UPPER RESPIRATORY TRACT INFECTION", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 44}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 21}]}, {"term": "HEADACHE", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 44}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 21}]}, {"term": "ASTHMA", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 44}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 21}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis", "phone": "862-778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}}, "hasResults": true}